Numeric sex chromosome abnormalities are commonly associated with an increased cancer risk. Here, we report a 14-year-old boy with a rare mosaic 45, X/48, XYYY karyotype presenting with subtle dysmorphic features and relative height deficiency, requiring growth hormone therapy. As only 12 postnatal cases have been described so far with very limited follow-up data, to assess the proband’s long-term prognosis, including cancer risk, we performed high-throughput single-cell RNA sequencing (scRNA-seq) analysis. Although comprehensive cytogenetic analysis showed seemingly near perfect balance between 45, X and 48, XYYY cell populations, scRNA-seq revealed widespread differences in genotype distribution among immune cell fractions, specifically in monocytes, B- and T-cells. These results were confirmed at DNA level by digital-droplet PCR on flow-sorted immune cell types. Furthermore, deregulation of predominantly autosomal genes was observed, including TCL1A overexpression in 45, X B-lymphocytes and other known genes associated with hematological malignancies. Together with the standard hematological results, showing increased fractions of monocytes and CD4+/CD8+T lymphocytes ratio, long-term personalized hemato-oncological surveillance was recommended in the reported patient.
According to EUROCAT, the European network of population-based congenital anomaly registries, chromosomal abnormalities occur in 43.6/10,000 live births with trisomies 21, 18 and 13, and the sex chromosomes abnormalities being the most common1. The prevalence of males with extra Y chromosomes, such as 47, XYY, 48, XYYY or 49, XYYYY, is much lower, but is difficult to determine it precisely as these subjects might appear phenotypically healthy until fertility issues arise in adulthood. The first 48, XYYY case was described over 50 years ago2 and only 11 additional individuals have been reported to date, including five mosaic (Table S1). Here, we report a 14-year-old boy presenting moderate height deficiency and mild dysmorphic features with a mosaic 45, X/48, XYYY karyotype. We performed a comprehensive cytogenetic and molecular analysis to better understand the mechanism behind this rare disorder and to provide the individual as well as his family with reliable information regarding his specific risk for clinical/cancer complications and therapeutic perspectives.
The child was conceived through assisted reproductive technology due to parental asthenospermia (intrauterine insemination procedure with homologous father’s semen). Born at term after an uneventful pregnancy with birth weight 4850 g and Apgar score 10, had psychomotor development in infancy and early childhood within the normal range. At the age of 8 the individual was referred to an endocrinologist due to a slower than expected mid-parental height growth rate (Fig. 1A). On physical examination, abnormal body proportions (greater sitting height than standing) and several dysmorphic features albeit resembling his father were noted (Fig. 1B). The patient was overweight with body mass index at 90–97th percentile (21.4 kg/m2) and had significantly accelerated bone maturity. Ultrasound images of thyroid gland, abdominal organs, heart and testes (Tanner stage 1) were normal. Subsequently, on magnetic resonance imaging an empty sella with the preserved signal from the posterior pituitary was observed, which prompted growth hormone (GH) stimulating testing. Results of clonidine and glucagon tests confirmed the diagnosis of somatotropin hypopituitarism and consequently GH treatment was applied at a dose of 0.018 mg/kg. Primary adrenal insufficiency and other hormonal abnormalities were ruled out by normal synthetic ACTH test results, pre-pubertal gonadotropin response in the LHRH test, normal pituitary TSH reserve in the synthetic TRH test and normal results of oral glucose tolerance test. The indistinct clinical picture and presence of multiple dysmorphic features, albeit mild, prompted further genetic analysis leading to diagnosis of 45, X/48, XYYY (Fig. 1C). At the most recent follow-up at 14.5 years of age, the proband’s height is at the 50th percentile as a result of a good response to GH treatment, with bone age appropriate for chronological age, which significantly improves the prognosis of his final height. Physical sexual development is according to his age (Tanner stage 3), but the perception of sexual interest is low in psychological evaluation. Ultrasound images of testicles are normal (6.2 ml and 6.5 ml testicle volume, respectively). Serum gonadotropin and testosterone levels are appropriate to the stage of sexual maturation. The patient’s intellectual functioning is average, with a Full Scale IQ score of 100 and no differences between nonverbal and verbal IQ. Extended psychological evaluation revealed no behavioral disorders, but difficulties in spatial orientation.
This study was approved by the Institutional Review Board and Ethics Committee at the Medical University of Gdansk (NKBBN/215/2020) and all methods were carried out in accordance with relevant guidelines and regulations. The individual’s parent(s) provided written informed consent prior to the start of the study. Whole blood, buccal swabs and/or fibroblasts were collected from the proband and his father. Fluorescence-activated cell sorting (FACS) and DNA extraction were performed in accordance with the manufacturers’ protocols (details in “Samples collection and sorting of blood cell with fluorescence-activated cell sorting (FACS)” and “DNA extraction” in the Supplementary Information). The initial genetic work-up included conventional karyotyping and fluorescent in situ hybridization (FISH) analyses of lymphocytes and cultured skin fibroblasts, followed by chromosomal microarray analysis (CMA), chromosome Y short-tandem repeat (Y-STR) haplotyping and digital droplet PCR (ddPCR) of FACS-sorted cells (details in “Cytogenetic and molecular studies” in the Supplementary Information). To assess the risk of hematological complications the standard diagnostic analysis was performed, including a complete blood count, microscopy and a flow cytometry immunophenotyping. Single-cell RNA sequencing analysis (scRNA-seq) was performed on freshly isolated peripheral blood mononuclear cells (PBMCs) according to the manufacturer’s protocol and raw data analysis was done with the CellRanger software (10xGenomics). Further data processing was performed in R and Seurat to normalize, cluster and visualize the scRNA-seq data, and to identify cells with or without chromosome Y3. All statistical analysis were done in R computational environment. SingleR, followed by manual curation, was used to label the individual immune cell types. Differential gene expression with integration and comparison against healthy male controls was again done in R and Seurat. All methodological details related to the scRNA-seq analysis are provided in the following sections of the Supplementary Information, i.e. “scRNA-seq analysis”, “Processing of scRNA-seq data”, “Estimating mosaicism at single-cell level”, “Comparison against public PBMC data” and “Differential expression analyses”.
Cytogenetic analysis revealed the presence of a mosaic 45, X/48, XYYY karyotype with mosaicism proportion of 44–62% for 48, XYYY cell population (Figs. 1C, S1). Normal karyotypes were reported in parents’ peripheral blood; the father had also a normal karyotype in fibroblasts (Fig. S1). No additional genomic imbalances were observed in the proband’s karyotype by CMA and Y-STR haplotype analyses (Figs. S2, S3). In terms of scRNA-seq, the total number of good quality cells was 2936 with a median of 2066 genes and 7400 UMI counts per cell (Tables S2, S3). Expression-based clustering and visualization of the data in a two-dimensional space yielded twelve distinct clusters representing eight major types of immune cells (Figs. 2A–B, S4, Tables S4, S5), reflecting physiological proportions seen in PBMCs. The status of each individual cell (45, X or 48, XYYY) was determined by detecting the presence or a complete absence of Y-linked expression (Fig. S5 and Table S6). In total, the cells with and without chromosome Y constituted 48.43% and 51.57%, respectively (Table S7). This nearly perfect balance was no longer observed when analyzing individual immune cell fractions, i.e. T-cell populations were mostly composed of 48, XYYY cells, while B cells and monocytes of 45,X cells. These results were confirmed by an independent molecular method, i.e. ddPCR on FACS-sorted cells (Figs. 2C–D, 3 and Table S8). The high frequencies of triple Y cells were accompanied with significantly higher expression from Y chromosome genes (Figs. 2E, S6), with a lower Y/X ratio observed in PBMCs of healthy male controls (Fig. S7). Comparison of gene expression between the major immune cell populations with 45, X and 48, XYYY karyotypes revealed a list of 31 genes whose expression differed significantly (DEGs) (Wilcoxon rank sum test with a Bonferroni-adjusted p value < 0.05), including 13 genes potentially related to cancer/hematological complications (Fig. 3, Tables S9, S10). Hematological profile was within normal range, except for a borderline value of classical monocytes (91.3%) and an increased ratio (2.6:1) of CD4+ versus CD8+ T lymphocytes (Fig. S8 and Table S11).
We report here the first comprehensive molecular analysis of a pre-pubertal individual with a rare mosaic 48, XYYY karyotype. Because only 12 postnatal cases have been described so far with limited follow-up data, the individual’s long-term prognosis, including cancer risk, was difficult to predict. The combination of cytogenetic and scRNA-seq analyses along with the detailed clinical information resulted in providing personalized care to the patient and his family.
Sex chromosome aneuploidy may affect physical, developmental, behavioral and cognitive functioning, with each extra chromosome increasing the severity4, in line with the previous 48, XYYY case reports (Table S1). In contrast to these observations, the individual described in this study did not have gross birth defects, a rather normal psychomotor development and intellectual functioning. The genetic diagnosis was prompted by the presence of very subtle dysmorphic features and moderate height deficiency, signs not considered to be cardinal for the Y chromosome polysomy.
There are two well described mechanisms underlying gains and losses of whole chromosomes, i.e. mitotic or meiotic nondisjunction, when chromosomes do not properly separate and one daughter cell miss a chromosome that may be gained by the other daughter cell, and, less commonly, structural chromosomal abnormalities that might result in aneuploidy as well. We likely excluded the possibility that the proband carries other structural unbalanced rearrangements or copy number neutral loss-of-heterozygosity by performing chromosomal SNP microarray analysis (Fig. S2). Hence, nondisjunction(s) appear(s) to be the more likely explanation. In the case of the double Y chromosomes (47, XYY), the nondisjunction could readily explain this abnormality, but this is not explanatory for 48, XYYY. Moreover, we cannot exclude the possibility of conceiving a normal ovum by a YYY-sperm that was a result of errors in spermatogenesis through nondisjunction or anaphase lagging. It is noteworthy that the proband’s father had normal karyotype in peripheral blood and fibroblasts, analyzed by two cytogenetic techniques, i.e. the classical GTG-banding karyotyping at the 550-band stage of resolution and FISH with a much higher resolution (Fig. S1). In order to exclude the latter potential mechanism, the father’s testicular tissue biopsy should have been performed as this tissue could be mosaic. However, in line with the research ethics protocols, there was no indications for performing such an invasive medical procedure. Furthermore, gonosomal mosaicism of the father for the 48, XYYY genotype does not explain presence of 45, X lineage in the proband. Yet another possible explanation is a series of nondisjunction of the Y chromosome in a normal zygote. However, in that scenario we should have detected at least four cell lineages: 45, X, 46, XY, 47, XYY and 48, XYYY that originated via nondisjunction in the course of subsequent cellular divisions. As we showed in Figs. 1C, S1, only 45, X and 48, XYYY cell lines were identified in the reported patient. Hence, the 46, XY and 47, XYY should have been eliminated during the ontogenesis or might be present in other tissues/organs that were not sampled. Altogether, due to the very strong speculative nature, these potential mechanism(s) needs to be interpreted with caution.
As the proband has a mosaic karyotype with a 45, X cell lineage and, considering the increased risk for gonadal tumors in women with Turner syndrome and a Y mosaic genotype5, the relevant question is whether the bilateral prophylactic gonadectomy applies. Evaluation of clinical guidelines for timing of gonadectomy shows substantial inconsistencies. Current recommendations advocate individualized and conservative approach by taking into account specific location of the gonads (scrotal or non-scrotal), the internal and external phenotype and sex of rearing6. GH therapy, usually implemented in women with Turner syndrome, is another risk factor of neoplasia development7, thus the pros and cons should be considered before going ahead with the treatment.
Loss of chromosome Y (LOY) in blood of ageing men has been correlated with shorter survival and higher risk of non-hematological cancer mortality8. Several case reports of 47,XYY males also demonstrate the increased risk for various neoplasms, mostly for hematological malignancies9,10,11,12,13,14. Notably, large epidemiological study by Jorgensen et al.15 on 82 individuals with 47, XYY syndrome did not confirm these observations, but the median age of the studied cohort was only 12.7 years old. Considering the occurrence of these specific cancer risk factors, including, but not limited to gonadal tumors, and the ongoing GH therapy, it was crucial from the clinical perspective to evaluate the overall cancer risk in the individual described here.
Single-cell sequencing provided a powerful personalized medicine approach to tailor the clinical management and targeted therapy16. The scRNA-seq transcriptomic analysis performed in this study confirmed the equal proportions of 45, X and 48, XYYY cell lineages in a PBMC sample, in line with the standard cytogenetics results (details in Supplementary Information). However, we demonstrated that these proportions differ between the individual’s specific immune cell fractions, with up to two times greater fold change for monocytes, B- and T-cells (Figs. 2, 3 and Table S12). These findings suggest that the numerical Y chromosome abnormalities likely have an effect on hematopoietic cells, and should not be considered as a neutral event. While several studies show the association between LOY and aberrant clonal expansion of cells17,18, the role of an extra Y chromosome cannot be excluded. Comparative analysis against an independent cohort of healthy males revealed that the high frequencies of triple Y cells in proband were accompanied with significantly higher expression from the Y chromosome (Figs. 2E, S6). Nevertheless, further studies are required to fully understand the mechanism underlying the clonal expansion.
Detailed examination of the identified DEGs revealed dysregulation of a considerable number of autosomal genes (Fig. 3). Enrichment analysis performed to understand the biological significance of transcriptional changes showed that these genes are important for a range of physiological functions. Altogether they encode regulators of stem/progenitor cell commitment and bridges between innate and adaptive immune responses. Besides, as components of immunosurveillance machinery they are directly involved in T-cell signaling, which might provide a possible explanation for the frequency discrepancy of T lymphocytes between populations of 45, X and 48, XYYY cells (Table S13). Notably, 6/31 autosomal genes are associated with hematological malignancies (Table S10), including TCL1A (MIM * 186960), a known leukemia/lymphoma risk factor. The protein encoded by TCL1A acts as a co-activator of the cell survival kinase AKT with the overexpression usually observed in hematological malignancies of T and B cells19. Our findings demonstrate that TCL1A expression is dysregulated in CD19+B cells, in line with the previous studies18,20. However, the mechanisms of its regulation are largely unknown. GWAS studies reported recently that specific single nucleotide polymorphisms near TCL1A (rs2887399) might be associated with the predisposition to LOY17,20,21, but this genotype was not present in the proband (Fig. S2).
Given all evidence from the previous and the current studies, hematological surveillance of patients with numerical Y chromosome abnormalities is advisable. Although standard hematological analysis has not revealed now any significant abnormalities in the presented individual, except for increased fractions of monocytes and CD4+/CD8+T lymphocytes ratio that do require follow-up, it should be kept in mind that the proband is a 14-year-old boy before puberty, hence he was referred to periodic hematological evaluation, pending possible bone marrow biopsy.
In conclusion, specific hematological malignancy risk in GH-treated phenotypic males with 45, X/48, XYYY mosaicism is understudied and remains to be ascertained. Transcriptomic results presented here are concerning and point to the need for careful hematological surveillance in these patients. Obviously, a close follow-up of the testes, including regular clinical and sonographic evaluation and IGF-I evaluation while on GH treatment, is mandatory. As most adult males reported to date with 48, XYYY karyotype were diagnosed with azoospermia, likely due to decreased testicular function at the end of puberty, early fertility preservation strategies might also be considered. This study highlights the clear synergistic effects and clinical utility of close translational collaboration between the research laboratory and the clinic enabling genotype-driven personalized medicine.
Raw, de-identified RNA-sequencing files were deposited in European Genome-Phenome Archive (https://ega-archive.org/): accession no. EGAS00001005697 (EGAD00001008645). The code used to process the data described in this study is available at: https://github.com/jakalssj3/45X_48XYYY.
Wellesley, D. et al. Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe. Eur. J. Hum. Genet. 20, 521–526 (2012).
Townes, P. L., Ziegler, N. A. & Lenhard, L. W. A patient with 48 chromosomes (XYYY). Lancet 1, 1041–1043 (1965).
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
Linden, M. G., Bender, B. G. & Robinson, A. Sex chromosome tetrasomy and pentasomy. Pediatrics 96, 672–682 (1995).
Gravholt, C. H. et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 cincinnati international turner syndrome meeting. Eur. J. Endocrinol. 177, G1-70 (2017).
McCann-Crosby, B. et al. State of the art review in gonadal dysgenesis: Challenges in diagnosis and management. Int. J. Pediatr. Endocrinol. 1, 4 (2014).
Gawrychowska, A. et al. Dysgerminoma with a somatic exon 17 KIT mutation and SHH pathway activation in a girl with Turner syndrome. Diagnostics 10, 1067 (2020).
Forsberg, L. A. et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet. 46, 624–628 (2014).
Xiao, H., Dadey, B., Block, A. W., Han, T. & Sandberg, A. A. Extra Y chromosome in chronic lymphoproliferative disorders. Cancer Genet Cytogenet. 51, 207–213 (1991).
Taub, J. W. et al. Acute lymphoblastic leukemia in a 46, X/47, XYY mosaic male: clonal origin of leukemia in the XY-bearing stem-cell line. Am. J. Dis. Child. 147, 1254–1255 (1993).
Trivedi, A. H. et al. An XYY male with acute lymphoblastic leukemia. Cancer Genet. 83, 178 (1995).
Oguma, N., Shigeta, C. & Kamada, N. XYY male and hematologic malignancy. Cancer Genet. Cytogenet. 90, 179–181 (1996).
Palanduz, S. et al. 47, XYY karyotype in acute myeloid leukemia. Cancer Genet. 106, P76–P77 (1998).
Jo, H. C., Lee, S. W., Jung, H. J. & Park, J. E. Esthesioneuroblastoma in a boy with 47, XYY karyotype. Clin. Exp. Pediatr. 59, S92–S95 (2016).
Jorgensen, I. F. et al. Comorbidity landscape of the Danish patient population affected by chromosome abnormalities. Genet. Med. 21, 2485–2495 (2019).
Kim, D. et al. Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: A case report. Nature 26, 236–243 (2020).
Terao, C. et al. GWAS of mosaic loss of chromosome Y highlights genetic effects on blood cell differentiation. Nat. Commun. 10, 4719 (2019).
Dumanski, J. P. et al. Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. Cell Mol. Life Sci. 78, 4019–4033 (2021).
Laine, J., Kunstle, G., Obata, T., Sha, M. & Noguchi, M. The protooncogene TCL1 is an Akt kinase coactivator. Mol. Cell 6, 395–407 (2000).
Thompson, D. J. et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature 575, 652–657 (2019).
Zhou, W. et al. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nat. Genet. 48, 563–568 (2016).
Kułaga, Z. et al. Siatki centylowe wysokości, masy ciała i wskaźnika masy ciała dzieci i młodzieży w Polsce - wyniki badania OLAF. Standardy medyczne/Pediatria 7, 690–700 (2010).
We appreciate the cooperation of the patient and his parents during work on this report. We thank Dr. Arkadiusz Mański from the Psychological Counseling Centre for Rare Genetic Diseases and Institute of Psychology, University of Gdansk (Poland) for assistance in conducting, analyzing and interpreting the Stanford-Binet Intelligence Scales. The proband’s clinical images were taken and edited for research purposes by Paweł Sudara (Medical University of Gdansk) and Szymon Kościelniak. The study was supported by a research grant program Young Creator of Science (664/503/61/71-1401) as a part of the “Excellence Initiative - Research University Program” to M.K. and by the Foundation for Polish Science (FNP) under the International Research Agendas Program (grant number MAB/2018/6) to J.P.D and A.P, co-financed by the European Union under the European Regional Development Fund.
All authors declare no conflict of interest, except for J.P.D. who is a co-founder and shareholder in Cray Innovation AB.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Koczkowska, M., Jąkalski, M., Birkholz-Walerzak, D. et al. Personalized health risk assessment based on single-cell RNA sequencing analysis of a male with 45, X/48, XYYY karyotype. Sci Rep 12, 20854 (2022). https://doi.org/10.1038/s41598-022-25308-w
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.